NCT01831973View on ClinicalTrials.gov

A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 19, 2015

Study Completion Date

February 21, 2017

Conditions
Advanced/Metastasis Renal Cell Carcinoma
Interventions
DRUG

Lipotecan

Trial Locations (5)

333

Chang Gung Memorial Hospital: LinKou Branch, Taoyuan District

404

China Medical University Hospital, Taichung

407

Taichung Veterans General Hospital, Taichung

833

Chang Gung Memorial Hospital. Kaohsiung Branch, Kaohsiung City

10002

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Taiwan Liposome Company

INDUSTRY

NCT01831973 - A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients | Biotech Hunter | Biotech Hunter